Log in

NASDAQ:ARLZ - Aralez Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume5.13 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Aralez Pharmaceuticals Inc operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ARLZ
CUSIP73941U10
Phone905-876-1118

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableOptionable

Receive ARLZ News and Ratings via Email

Sign-up to receive the latest news and ratings for ARLZ and its competitors with MarketBeat's FREE daily newsletter.


Aralez Pharmaceuticals (NASDAQ:ARLZ) Frequently Asked Questions

What is Aralez Pharmaceuticals' stock symbol?

Aralez Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARLZ."

How were Aralez Pharmaceuticals' earnings last quarter?

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) released its quarterly earnings results on Thursday, November, 9th. The company reported ($0.37) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.39) by $0.02. The business had revenue of $24.30 million for the quarter, compared to analyst estimates of $22.87 million. The company's revenue for the quarter was up 78.7% on a year-over-year basis. During the same period in the prior year, the business earned ($0.32) earnings per share. View Aralez Pharmaceuticals' Earnings History.

Has Aralez Pharmaceuticals been receiving favorable news coverage?

News coverage about ARLZ stock has been trending very negative this week, according to InfoTrie. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Aralez Pharmaceuticals earned a news impact score of -3.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Aralez Pharmaceuticals.

Who are some of Aralez Pharmaceuticals' key competitors?

What other stocks do shareholders of Aralez Pharmaceuticals own?

Who are Aralez Pharmaceuticals' key executives?

Aralez Pharmaceuticals' management team includes the folowing people:
  • Mr. Adrian Adams, CEO & Director (Age 67)
  • Mr. Andrew I. Koven, Pres & Chief Bus. Officer (Age 60)
  • Mr. Michael Kaseta, Chief Financial Officer (Age 42)
  • Dr. James Patrick Tursi, Chief Medical Officer (Age 53)
  • Mr. John E. Barnhardt CPA, Principal Accounting Officer and VP of Fin. & Admin. (Age 68)

What is Aralez Pharmaceuticals' official website?

The official website for Aralez Pharmaceuticals is http://www.aralez.com/.

How can I contact Aralez Pharmaceuticals?

Aralez Pharmaceuticals' mailing address is 7100 WEST CREDIT AVENUE SUITE 101, MISSISSAUGA A6, L5N 0E4. The company can be reached via phone at 905-876-1118 or via email at [email protected]


MarketBeat Community Rating for Aralez Pharmaceuticals (NASDAQ ARLZ)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  279 (Vote Outperform)
Underperform Votes:  290 (Vote Underperform)
Total Votes:  569
MarketBeat's community ratings are surveys of what our community members think about Aralez Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARLZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARLZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel